AstraZeneca Tagrisso gets approval in Japan for early-stage lung cancer subtype after surgery
Roland Magnusson/iStock Editorial via Getty Images                 

The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (NASDAQ:AZN)Â Tagrisso as an adjuvant therapy for patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after surgery.
The approval was backed by data from a global phase 3 trial calledÂ ADAURA.
The British pharma giant added that TagrissoÂ (osimertinib) is the only EGFR-targeted medicine approved in Japan to treat early-stage lung cancer after surgery.
The company noted that this is the third approved indication for Tagrisso in Japan, following previous approvals for 2nd-line T790M and 1st-line EGFRm NSCLC in March 2016 and August 2018, respectively.